David Schenkein, general partner at GV, on investing in the future of biotech.

The Long Run with Luke Timmerman

Ep170: David Schenkein on Investing in the Future of Biotech

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Ep174: Najat Khan on the TechBio Movement

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ep172: Mostafa Ronaghi on Studying Live Cells at Scale

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

Ep171: Ram Aiyar on RNA Editing Medicines

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Ep167: Leslie Williams on transfer RNA therapies

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.

Ep165: Zach Hornby on Tackling Cancer Drug Resistance

Science

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Ep170: David Schenkein on Investing in the Future of Biotech

The Long Run with Luke Timmerman

More episodes from "The Long Run with Luke Timmerman"

Ep174: Najat Khan on the TechBio Movement

Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders

Ep172: Mostafa Ronaghi on Studying Live Cells at Scale

Ep171: Ram Aiyar on RNA Editing Medicines